Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates

Substance Abuse

Volumn 33, Issue 4, 2012, Pages 336-349

  Gorsane, Mohamed Ali ^a,b,c   Kebir, Oussama ^a,d   Hache, Guillaume ^c   Blecha, Lisa ^a,b,c   Aubin, Henri Jean ^a,b,c   Reynaud, Michel ^a,b,c   Benyamina, Amine ^a,b,c  

^a INSERM   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Alcohol dependence; alcohol intake; baclofen; craving; relapse; safety; withdrawal

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN;

ADDICTION; ALCOHOLISM; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; DISEASE MODEL; HUMAN; RECURRENT DISEASE; REVIEW; WITHDRAWAL SYNDROME;

ALCOHOLISM; ANIMALS; BACLOFEN; BEHAVIOR, ADDICTIVE; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; DISEASE MODELS, ANIMAL; GABA-B RECEPTOR AGONISTS; HUMANS; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84866793724     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2012.663326     Document Type: Article

References (95)

1. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-1695
2. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373:2223-2233
3. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidencebased practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;278: 144-151
4. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des. 2010;16:2113-2137
5. Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets. 2010;9:33-44.
6. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat. 2009;36:S15-S23; quiz S4-S5
7. Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006;26:290-302
8. Barth KS, Malcolm RJ. Disulfiram: an old therapeutic with newapplications. CNS Neurol Disord Drug Targets. 2010;9:5-12
9. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today?. Addiction. 2004;99:21-24
10. Dahchour A, De Witte P, Bolo N, et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res. 1998;82:107-114
11. Berton F, Francesconi WG, Madamba SG, Zieglgansberger W, Siggins GR. Acamprosate enhances Nmethyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res. 1998;22:183-191
12. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996;13:35-39
13. Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict. 2001;10:258-268
14. Widdowson PS, Holman RB. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates. J Neurochem. 1992;59:157-163
15. Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 1993;621:137-140
16. Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18: 54-59
17. Gueorguieva R, Wu R, Donovan D, et al. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study. Alcohol Clin Exp Res. 2011;35(3):523-531
18. Soyka M, Rosner S. Emerging drugs to treat alcoholism. Expert Opin Emerg Drugs. 2010;15:695-711
19. Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther. 1986;239:219-228
20. Di Chiara G, Imperato A. Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats. Eur J Pharmacol. 1985;115:131-132
21. Redish AD. Addiction as a computational process gone awry. Science. 2004;306:1944-1947
22. Swift RM. Drug therapy for alcohol dependence. N Engl J Med. 1999;340:1482-1490
23. Steffensen SC, Svingos AL, Pickel VM, Henriksen SJ. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J Neurosci. 1998;18:8003-8015
24. Johnson SW, North RA. Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol. 1992;450:455-468
25. Silberman Y, Bajo M, Chappell AM, et al. Neurobiological mechanisms contributing to alcohol-stress-anxiety interactions. Alcohol. 2009;43:509-519
26. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006;111:855-876
27. Addolorato G, Leggio L, Cardone S, Ferrulli A, Gasbarrini G. Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol. 2009;43:559-563
28. Krnjevic K, Schwartz S. The action of gammaaminobutyric acid on cortical neurones. Exp Brain Res. 1967;3:320-336
29. Krnjevic K, Schwartz S. Is gamma-aminobutyric acid an inhibitory transmitter?. Nature. 1966;211:1372-1374
30. Chebib M, Johnston GA. The 'ABC' of GABA receptors: a brief review. Clin Exp Pharmacol Physiol. 1999;26:937-940
31. Kaupmann K, Malitschek B, Schuler V, et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature. 1998;396:683-687
32. McDonald AJ, Mascagni F, Muller JF. Immunocytochemical localization of GABABR1 receptor subunits in the basolateral amygdala. Brain Res. 2004;1018: 147-158
33. Misgeld U, Bijak M, Jarolimek W. A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol. 1995;46:423-462
34. Cryan JF, Kaupmann K. Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci. 2005;26:36-43
35. Keberle H, Faigle JW, Wilhelm M. Procedure for the preparation of new aminioacids. Patent no.: GB1017439. January 19, 1966. Available at: http://www.wikipatents.com/GB-Patent-1017439/new-amino-acids-andprocess-for- preparing-same. Accessed August 7, 2012
36. Doherty M, Gratton A. Differential involvement of ventral tegmentalGABA(A) andGABA(B) receptors in the regulation of the nucleus accumbens dopamine response to stress. Brain Res. 2007;1150:62-68
37. Giorgetti M, Hotsenpiller G, Froestl W, Wolf ME. In vivo modulation of ventral tegmental area dopamine and glutamate efflux by local GABA(B) receptors is altered after repeated amphetamine treatment. Neuroscience. 2002;109:585-595
38. Colombo G, Agabio R, Carai MA, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I-preclinical evidence. Alcohol Clin Exp Res. 2000;24:58-66
39. Cousins MS, Roberts DC, de Wit H. GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend. 2002;65:209-220
40. Broft AI, Spanos A, Corwin RL, et al. Baclofen for binge eating: an open-label trial. Int J Eat Disord. 2007;40:687-691
41. ArimaH,OisoY. Positive effect of baclofen on body weight reduction in obese subjects: a pilot study. Intern Med. 2010;49:2043-2047
42. Theile JW, Morikawa H, Gonzales RA, Morrisett RA. Ethanol enhances GABAergic transmission onto dopamine neurons in the ventral tegmental area of the rat. Alcohol Clin Exp Res. 2008;32:1040-1048
43. Maccioni P, Colombo G. Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. Alcohol. 2009;43:555-558
44. Quintanilla ME, Perez E, Tampier L. Baclofen reduces ethanol intake in high-alcohol-drinking University of Chile bibulous rats. Addict Biol. 2008;13:326-336
45. Colombo G, Serra S, Vacca G, Carai MA, Gessa GL. Baclofen-induced suppression of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats exposed to different alcohol concentrations. Eur J Pharmacol. 2006 21;550:123-126
46. Besheer J, Lepoutre V, HodgeCW.GABA(B) receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice. Psychopharmacology (Berl). 2004;174:358-366
47. Walker BM, Koob GF. The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res. 2007;31:11-18
48. Colombo G, Vacca G, Serra S, Brunetti G, Carai MA, Gessa GL. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (Berl). 2003;167:221-224
49. Maccioni P, Bienkowski P, Carai MA, Gessa GL, Colombo G. Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend. 2008 1;95:284-287
50. Martz A, Deitrich RA, Harris RA. Behavioral evidence for the involvement of gamma-aminobutyric acid in the actions of ethanol. Eur J Pharmacol. 1983;89:53-62
51. Camarini R, Marcourakis T, Teodorov E, Yonamine M, Calil HM. Ethanol-induced sensitization depends preferentially on D1 rather than D2 dopamine receptors. Pharmacol Biochem Behav. 2011;98:173-180
52. Broadbent J, Harless WE. Differential effects of GABA(A) and GABA(B) agonists on sensitization to the locomotor stimulant effects of ethanol in DBA/2 J mice. Psychopharmacology (Berl). 1999;141:197-205
53. Arias C,Mlewski EC,Molina JC, Spear NE. Naloxone and baclofen attenuate ethanol's locomotor-activating effects in preweanling Sprague-Dawley rats. Behav Neurosci. 2009;123:172-180
54. Boehm SL, 2nd, PiercyMM,Bergstrom HC, Phillips TJ. Ventral tegmental area region governs GABA(B) receptor modulation of ethanol-stimulated activity in mice. Neuroscience. 2002;115:185-200
55. Chester JA, Cunningham CL. Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice. Pharmacol Biochem Behav. 1999;63:325-331
56. Cott J, Carlsson A, Engel J, Lindqvist M. Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn Schmiedebergs Arch Pharmacol. 1976;295:203-209
57. Knapp DJ, Overstreet DH, Breese GR. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcoholism. 2007;31:582-595
58. File SE, ZharkovskyA,GulatiK. Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat. Neuropharmacology. 1991;30:183-190
59. Colombo G, Serra S, Vacca G, Gessa GL, Carai MA. Suppression by baclofen of the stimulation of alcohol intake induced by morphine andWIN 55,212-2 in alcoholpreferring rats. Eur J Pharmacol. 2004 25;492:189-193
60. Skinner MD, Aubin HJ. Craving's place in addiction theory: contributions of the major models. Neurosci Biobehav Rev. 2010;34:606-623
61. Bottlender M, Soyka M. Impact of craving on alcohol relapse during, and 12 months following, outpatient treatment. Alcohol Alcohol. 2004;39:357-361
62. Miller WR, Westerberg VS, Harris RJ, Tonigan JS. What predicts relapse?. Prospective testing of antecedent models. Addiction. 1996;91(Suppl):S155-S172
63. Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II-preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24:67-71
64. Addolorato G, Cibin M, Caputo F, et al. Gammahydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients. Drug Alcohol Depend. 1998;53:7-10
65. Ling W, Shoptaw S, Majewska D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology. 1998;18:403-404
66. Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res. 2004;28:1517-1523
67. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893-897
68. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999;23:1289-1295
69. Steer RA,McElroyMG,Beck AT.Correlates of selfreported and clinically assessed depression in outpatient alcoholics J Clin Psychol. 1983 39:144-149
70. Leggio L, Ferrulli A, Cardone S, et al. Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. Alcohol. 2008;42:375-381
71. Leggio L, Ferrulli A, Malandrino N, et al. Insulin but not insulin growth factor-1 correlates with craving in currently drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2008;32:450-458
72. Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19:92-99
73. Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets. 2010;9:33-44
74. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 2005;40:147-150
75. Ameisen O. Le dernier verre [The Last Glass]. Paris: Denöel; 2008
76. Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. A system of prescriptions without drug approval: example of baclofen. Therapie. 2010;65:511-518
77. Ameisen O, de Beaurepaire R. Suppression de la d́ependance ̀a l'alcool et de la consommation d'alcool par le baclof̀ene ̀a haute dose: un essai en ouvert. Ann Ḿed Psychol Rev Psychiatr. 2010;168:159-162
78. de Beaurepaire R. Baclofen for the treatment of alcoholism. PSN Psychiatr Sci Hum Neurosci. 2011;9:1-6
79. Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol. 2007;42:158-160
80. Agabio R, Marras P, Addolorato G, Carpiniello B, Gessa GL. Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. J Clin Psychopharmacol. 2007;27:319-320
81. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37:504-508
82. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370:1915-1922
83. Spielberg CD, Gorsuch RL, Lushene RE. Manual for the State and Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologist Press; 1983
84. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebocontrolled trial. Alcohol Clin Exp Res. 2010;34:1849-1857
85. Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63-70
86. Garbutt JC, Flannery B. Baclofen for alcoholism. Lancet. 2007;370:1884-1885
87. Addolorato G, Leggio L, Ferrulli A, et al. Doseresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011;46(3):312-317
88. Liu J, Wang L. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev. 2011;(1):CD008502
89. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353-1357
90. Addolorato G, Caputo F, Capristo E, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med. 2002;112:226-229
91. Addolorato G, Leggio L, Abenavoli L, et al. Suppression of alcohol delirium tremens by baclofen administration: a case report. Clin Neuropharmacol. 2003;26:258-262
92. Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med. 2006;119:276 e13-e18
93. Dario A, Scamoni C, Picano M, Casagrande F, Tomei G. Pharmacological complications of the chronic baclofen infusion in the severe spinal spasticity. Personal experience and review of the literature. J Neurosurg Sci. 2004;48:177-181
94. Soufia M, Plaze M, Gueguen B, Demigneux G, Olie JP, Gaillard R. Behavioral disinhibition with baclofen. J Clin Psychopharmacol. 2010;30:759-760
95. Evans SM, Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res. 2009;33:19-30